anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The management of factor Xa (FXa) inhibitor-associated bleeding remains a clinical challenge. Massive bleeding is often associated with complex coagulopathy and, thus, the sole reversal of FXa inhibitors might not be sufficient to restore hemostasis, requiring instead a multimodal approach. Four-factor prothrombin complex concentrate (4F-PCC) is widely recognized as a viable treatment option for FXa inhibitor-associated bleeding. Here, we applied computational models to explore the effect 4F-PCC has on the coagulation cascade and restoration of thrombin generation in a system that simulates a patient that has received a FXa inhibitor. The coagulation model is largely based on a previously developed model with modifications incorporated from various other published sources. The model was calibrated and validated using data from a phase 3 clinical trial of vitamin K antagonist reversal with 4F-PCC. Using the parameters and initial conditions determined during the calibration and validation process, the prothrombin time (PT) test simulations predicted a PT of 11.4 seconds. The model successfully simulated the effects of rivaroxaban and apixaban on total thrombin concentration and showed that 4F-PCC increased thrombin generation in the presence of rivaroxaban or apixaban.
The safety and effectiveness of ATORVALIQ as an adjunct to diet to reduce LDL-C have been established pediatric patients 10 years of age and older with HeFH. Use of ATORVALIQ for this indication is based on a double-blind, placebo-controlled clinical trial of atorvastatin in 187 pediatric patients 10 years of age and older with HeFH [see Clinical Studies (14)]. In this limited controlled trial, there was no significant effect on growth or sexual maturation in the boys or girls, or on menstrual cycle length in girls.

The safety and effectiveness of ATORVALIQ as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established pediatric patients 10 years of age and older with HoFH. . Use of ATORVALIQ for this indication is based on a trial of atorvastatin without a concurrent control group in 8 pediatric patients 10 years of age and older with HoFH [see Clinical Studies (14)].

The safety and effectiveness of ATORVALIQ have not been established in pediatric patients younger than 10 years of age with HeFH or HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).
Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
BACKGROUND: Subacute Sclerosing Panencephalitis (SSPE) typically presents with periodic myoclonus; however, a spectrum of movement disorders including dystonia, chorea, tremor, and parkinsonism have also been described. This review aims to evaluate the array of movement disorders in SSPE, correlating them with neuroimaging findings, disease stages, and patient outcomes.
METHODS: A comprehensive review of published case reports and case series was conducted on patients with SSPE exhibiting movement disorders other than periodic myoclonus. PRISMA guidelines were followed, and the protocol was registered with PROSPERO (2023 CRD42023434650). A comprehensive search of multiple databases yielded 37 reports detailing 39 patients. Dyken's criteria were used for SSPE diagnosis, and the International Movement Disorders Society definitions were applied to categorize movement disorders.
RESULTS: The majority of patients were male, with an average age of 13.8 years. Approximately, 80% lacked a reliable vaccination history, and 39% had prior measles infections. Dystonia was the most common movement disorder (49%), followed by parkinsonism and choreoathetosis. Rapid disease progression was noted in 64% of cases, with a disease duration of ≤6 months in 72%. Neuroimaging showed T2/FLAIR MR hyperintensities, primarily periventricular, with 26% affecting the basal ganglia/thalamus. Brain biopsies revealed inflammatory and neurodegenerative changes. Over half of the patients (56%) reached an akinetic mute state or died.
CONCLUSION: SSPE is associated with diverse movement disorders, predominantly hyperkinetic. The prevalence of dystonia suggests basal ganglia dysfunction.
AIMS: Doxorubicin (DXR) is a chemotherapeutic agent that causes dose-dependent cardiotoxicity. Recently, it has been proposed that the NADase CD38 may play a role in doxorubicin-induced cardiotoxicity (DIC). CD38 is the main NAD+-catabolizing enzyme in mammalian tissues. Interestingly, in the heart, CD38 is mostly expressed as an ecto-enzyme that can be targeted by specific inhibitory antibodies. The goal of the present study is to characterize the role of CD38 ecto-enzymatic activity in cardiac metabolism and the development of DIC.
METHODS AND RESULTS: Using both a transgenic animal model and a non-cytotoxic enzymatic anti-CD38 antibody, we investigated the role of CD38 and its ecto-NADase activity in DIC in pre-clinical models. First, we observed that DIC was prevented in the CD38 catalytically inactive (CD38-CI) transgenic mice. Both left ventricular systolic function and exercise capacity were decreased in wild-type but not in CD38-CI mice treated with DXR. Second, blocking CD38-NADase activity with the specific antibody 68 (Ab68) likewise protected mice against DIC and decreased DXR-related mortality by 50%. A reduction of DXR-induced mitochondrial dysfunction, energy deficiency, and inflammation gene expression were identified as the main mechanisms mediating the protective effects.
CONCLUSION: NAD+-preserving strategies by inactivation of CD38 via a genetic or a pharmacological-based approach improve cardiac energetics and reduce cardiac inflammation and dysfunction otherwise seen in an acute DXR cardiotoxicity model.
Participants engage in up to five 70-minute sessions of ASPIRE spread over a period of 5 weeks. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Baseline survey again completed. About one month after assessment 4, this group receives a 5th assessment followed by a hybrid version of the GSA-ASPIRE-Network program (moderated by Kahoot!). The group receives additional assessments after 3 sessions, following the last session of the program, and about one month after the program has ended (assessment 8).
BACKGROUND AND PURPOSE: The aim of this study was to determine the prevalence of anti-myelin-associated glycoprotein (MAG) neuropathy and the current status of such patients in Japan.
METHODS: We conducted a nationwide survey in 2021 using established epidemiological methods. Questionnaires were sent to all neurology and pediatric neurology departments throughout Japan to identify patients with anti-MAG neuropathy. An initial questionnaire was used to determine the number of patients, with a second one used to collect detailed clinical information.
RESULTS: The estimated number of patients with anti-MAG neuropathy was 353, with a prevalence of 0.28 per 100,000 and an incidence of 0.05 per 100,000. The detailed clinical profiles of 133 patients were available. The median (range) age of onset was 67 (30-87) years, with a prominent peak in the age range 66-70 years, and the male-to-female ratio was 3.6. Most patients had distal sensory-predominant polyneuropathy, and neuropathic pain (50%), or sensory ataxia (42%), while 18% had Waldenström's macroglobulinemia or multiple myeloma. Intravenous immunoglobulin was the most frequently used treatment (65%), but the response rate was <50%, whereas rituximab was given in 32% of patients, and 64% of these showed improvement. At the last visit, 27% of patients could not walk independently.
CONCLUSIONS: This study on anti-MAG neuropathy provides updated insights into the epidemiology of this disease, clinical profiles, and treatment approaches in Japan. Rituximab therapy, used for only one-third of the patients, demonstrated efficacy. During the final visit, a quarter of the patients were unable to walk independently. Further studies are warranted to determine the optimal management of this rare and intractable disorder.
All participants will receive a finite course of multiple IV dose administrations of PBGENE-HBV. In Part 1, this will be done in a dose escalation manner which may be evaluated further in a Part 2 expansion cohort.
Participants weighing (\>=)14 kg at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h. Participants weighing (\>=)10 kg to less than (\<)14 kg received ELX 80 mg qd/TEZ 40 mg qd/IVA 60 mg once every morning (qAM) and 59.5 mg once every evening (qPM) in the treatment period for 24 weeks.
The specific dose of methylprednisolone pulse therapy is 500mg / week \* 6 + 250mg / week \* 6. The effect of methylprednisolone pulse therapy on moderate and severe active Tao has been widely verified in clinical work. EUGOGO will take methylprednisolone pulse therapy as the first-line treatment of moderate and severe active Tao in 2020.
In the control group, the treatment is sodium chloride 0.9% administered with electric syringe. Infusion follows the same rules as in the experimental group.
An antibacterial and mucolytic composition, more especially a toothpaste, comprises lactic acid with or without a water-soluble lactate, e.g. calcium or sodium lactate, and ascorbic acid or a water-soluble salt thereof, the composition having a pH less than 7, when in association with an aqueous medium.  Specified ascorbic acid salts are the alkali metal, e.g. sodium salts.  The ascorbic acid may be in the form of the juice of citrus fruits, e.g. oranges, limes and lemons.  Acids such as citric or tartaric acid or acid salts may be added to lower the effective pH of the compositions in aqueous media which should preferably be in the range 5.5-7.0.  The compositions may be formulated as liquids, creamy, semi-solid or solid compositions, e.g. lotions, mouthwashes, powders or tablets.  In particular dentifrices contain humectants, e.g. glycerin, ethylene glycol, sorbitol or propylene glycol; surface-active agents, e.g. sodium lauryl sulphate; mild abrasives, e.g. calcium carbonate or sulphate, insoluble sodium meta-phosphate or dicalcium phosphate; binders or thickening-agents, e.g. water-soluble cellulose ethers, carboxy methyl cellulose, gum tragacanth or sodium alginate; perfume sweetening and flavouring agents, e.g. saccharin.  A composition for the treatment of vaginitis contains acid calcium lactate, ascorbic acid and phenyl mercuric nitrate.  The Provisional Specification describes also the use of methylene-blue, hypoxanthine or flavoproteins in place of the ascorbic constituent.  Specification 229,192 is referred to.
SNX-5422 is a prodrug for SNX-2112. Correlation has been observed between Hsp90 client protein level changes and functional effects in cells in in vitro studies of SNX-2112, supporting inhibition of Hsp90 as the mechanism of action for this compound. SNX-5422 has demonstrated significant antitumor activity in mouse xenograft models of human tumors, including breast (BT474, MX-1), colon (HT29), prostate (PC3), and melanoma (A375) with multiple oral dosing regimens. Pharmacokinetic (PK) studies in mice, rats, and dogs have shown high bioavailability of SNX-2112 following oral administration of SNX 5422. In mouse xenograft studies, SNX-2112 was selectively retained in tumor tissue compared with other tissues. This study will employ critical risk management features including the use of the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, which provides a scale for consistently grading the severity of AEs, toxicity criteria analyses for dose escalation, frequent laboratory and clinical observations, correlation of AEs with plasma concentrations of SNX-5422 and SNX-2112, monitoring of the QTc interval at appropriate time points, and a conservative dose-escalation scheme.
<P>PROBLEM TO BE SOLVED: To provide a new nuclear receptor termed the steroid and xenobiotic receptor (SXR), i.e. a new branch group of the nuclear receptor superfamily.  <P>SOLUTION: The SXR forms a heterodimer together with RXR(retinoid X receptor), reacts with hundreds of natural and synthetic substances having biological activity including therapeutic steroids as well as dietary steroids and lipids and induces transcription by binding with reaction elements present in steroid-inducible cytochrome P450 genes. The SXR receptor monitors aggregate levels of inducers for each one substance, instead of hundreds of receptors, to trigger production of metabolizing enzymes in a coordinated metabolic pathway. By administering agonists and antagonists of SXR to patients, a variety of therapeutic goals can be achieved through establishment of homeostasis depending on modulating metabolism of one or more endogeneous steroids or xenobiotics. An assay is provided for identifying steroid drugs likely causing drug interaction when administered to a patient in therapeutic amounts.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A single-centre, cross-over, open-label trial will be performed. Healthy volunteers, fulfilling the inclusion/exclusion criteria, will be asked to do blood samples and ultrasounds for the detection of the LH (luteinizing hormone) surge in a natural cycle. The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle, while the control group between day 6 and 8 of the cycle will have a mock catheter introduction without any Lipiodol flush. An endometrial biopsy will be performed 7 days after the LH peak in all the participants. Furthermore, all the participants will undergo one cycle with flushing and one cycle with introduction of a mock catheter but without flushing with any medication. The wash-out period between the 2 biopsies will be 3 months.
The dose-escalation of RO7122290 will use a QW dosing schedule of RO7122290 in combination with a Q3W dosing interval for cibisatamab with obinutuzumab pre-treatment. The starting dose for RO7122290 will be 35 mg, which represents the human equivalent dose for the minimal pharmacologically active dose (1 mg/kg) in mice.
This study assessed the effect of serum magnesium levels and their role in the outcome of allogeneic hematopoietic cell transplantation (allo-HSCT) in acute leukemia. Fifty-four patients with acute leukemia who underwent allo-HSCT were divided into two groups according to their serum magnesium levels before transplantation. The results showed that serum magnesium level is an independent factor influencing the prognosis of patients undergoing allo-HSCT. Low magnesium levels were associated with inferior overall survival and event-free survival compared with the associations of high magnesium levels (HR = 0.149; (95% CI: 0.029-0.755 for overall survival; HR = 0.369; 95% CI: 0.144-0.949, p = 0.039 for event-free survival). The competing risk model showed that the cumulative incidence of acute graft-versus-host disease was significantly low in the high magnesium group (p = 0.028). In general, there is a correlation between high magnesium levels and superior outcomes, including less and milder acute graft-versus-host disease, which does not affect cyclosporine-A levels. These findings provide valuable information for identifying the risk of poor prognosis in patients preparing for transplantation.
PURPOSE: To determine time to occlusion and procedure costs of embolization of pulmonary arteriovenous malformations (PAVMs) using a polytetrafluoroethylene-covered microplug compared with embolization using detachable coils.
MATERIALS AND METHODS: In this prospective study, 37 patients (mean age, 39.1 years [SD ± 17.6]) with 82 PAVMs underwent embolization with microplug or detachable coils between April 2019 and January 2023. Technical success, procedure time intervals, and costs were analyzed.
RESULTS: In 37 patients, 82 PAVMs and 101 feeding arteries were successfully treated (microplug, 64; microplug + another device, 5; detachable coils alone, 32). Time from embolic device inserted into the catheter to device deployed and time to occlusion differed significantly between microplug and detachable coil cohorts (P < .0001 for both). Embolization with ≥1 microplug had a significantly shorter occlusion time than embolization with detachable coils (median, 10.0 minutes saved per feeding artery) (P < .0001). Compared with detachable coil embolization, microplug embolization saved a median of 9.0 minutes per feeding artery (P < .0001) and reduced room cost by a median of $429 per feeding artery (P < .0001). Device costs per feeding artery did not differ significantly between microplug ($2,790) and detachable coil embolization ($3,147) (P = .87).
CONCLUSIONS: Compared with coils, microplugs had an equally high technical success rate but significant time to occlusion and room costs savings per feeding artery. Total room cost and device cost together did not differ significantly between microplugs and coils. Microplugs may be considered technically effective and at least cost-neutral for PAVM embolization where clinically appropriate.
This multi-center, observational, retrospective study collected real-world medical record data of patients with advanced ovarian cancer treated with niraparib as first-line maintenance therapy from fourteen hospitals in China. In reality, these patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death. A total of 199 patients were included in a centralized database ultimately with a median age of 57.0 years (range, 51.0-63.5 years).
PURPOSE:To provide a gel plate having excellent strength and useful especially as a base of a poultice, by dispersing a polysaccharide such as carrageenan in an aqueous solution of a polyhydric alcohol. CONSTITUTION:A polysaccharide or its derivative having gelling power (including a material developing the gelling power by the synergistic action with another material, e.g. a combination of guar gum and a boron compound, etc.), preferably carrageenan or a mixture of >=20% carrageenan and other polysaccharides is dispersed in an aqueous solution of a polyhydric alcohol (e.g. sorbit, glucose, etc.) containing water and the alcohol at a ratio of 95:5-40:60. If necessary, a third component is added to the dispersion, and the dispersion is heated to obtain a homogeneous solution. The solution is, if necessary after addition of a drug component, extruded through a slit or cast in the form of a flat plate, which is cooled to obtain the objective gel plate.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardiology and can be used to predict degree of restenosis development in coronary stent. For this purpose rate of nitrogen-containing preparation metabolism is determined by introduction the preparation into the test. As test-preparation introduced is caffeine in dose 150-300 mg orally once. After 6 hours ratio of N-acetyl-derivative of the preparation to non-metabolised preparation in urine is determined. If value of said ratio equals 73 % and lower favourable outcome of stenting is predicted. ^ EFFECT: said procedure ensures increase of accuracy in predicting degree of risk of restenosis development in coronary stent. ^ 3 ex
Neurodegenerative diseases (NDDs) pose a significant issue in healthcare, needing a thorough knowledge of their complex molecular mechanisms. A diverse set of cell signaling mediators and their interactions play critical roles in neuroinflammation. The release of pro-inflammatory mediators in response to neural dysfunction is detrimental to normal cell survival. Moreover, the important role of nuclear factor-κB (NF-κB) in the central nervous system through Toll-like receptor (TLR) activation has been well established. Therefore, through a comprehensive review of current research and experimentation, this investigation elucidates the interactions between novel pharmacological agents (TLR-4/NF-κB inhibitors) and neurodegeneration encompassing Alzheimer's, Parkinson's, Huntington's disease, amyotrophic lateral sclerosis and stroke. Insights garnered from this exploration underscore the potential of TLR-4 as a therapeutic target. Through the revelation of these insights, our aim is to establish a foundation for the development of enhanced and focused therapeutic approaches in the continuous endeavor to combat neurodegeneration. This review thus serves as a roadmap, guiding future research endeavors toward innovative strategies for combatting the complex interplay between TLR-4 signaling and NDDs.
The present invention relates to a nurse communication device ( 100 ). The nurse communication device ( 100 ) comprising patient monitoring unit and nurse calling button ( 101 ). The patient monitoring device and the nurse calling device both having indicator assembly. The individual nurse having individual RFID card which having all the personal information of the individuals. The nurse communication device ( 100 ) synchronous with the cloud through the router. The nurse communication device ( 100 ) easily paired with the voice assistant devices like siri or Alexa. The nurse calling device can provide facility to access real time data through the use of login credential. The application of the nurse communication device ( 100 ) generate accurate calling report consisting all the information like when patient called for nurse, who attended and at what time etc.
FIELD: medicine, gastroenterology. SUBSTANCE: invention relates to radiopharmaceutical composition used for diagnosis of digestive tract diseases. Radiopharmaceutical preparation comprises an aqueous solution of urea labeled with radionuclide carbon-14 and anhydrous sodium pyrophosphate placed into solid gelatin capsule and using as diagnostic agent in ulcer disease of digestive tract. Invention provides the enhanced precision of distribution of radioactive urea solution and cold carrier and rapid delivery of the preparation-containing capsule into stomach mucosa layer. EFFECT: enhanced and valuable properties of composition. 4 cl
Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.